Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108
June 11, 2024 08:30 ET | Palisade Bio, Inc.
PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio to Present at the Virtual Investor Pitch Conference
June 10, 2024 09:15 ET | Palisade Bio, Inc.
Live video webcast on Monday, June 17th at 12:00 PM ET Carlsbad, CA, June 10, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models
May 21, 2024 08:30 ET | Palisade Bio, Inc.
Data presented at Digestive Disease Week (DDW) 2024 Preclinical data demonstrate PALI-2108 to be safe, effective, and well tolerated PALI-2108 is orally delivered and colon-specific allowing...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024 08:05 ET | Palisade Bio, Inc.
– Company on track to commence Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end – Sufficient cash on hand to...
Picture1
Palisade Bio Appoints Margery Fischbein to its Board of Directors
May 07, 2024 08:30 ET | Palisade Bio, Inc.
Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globally Carlsbad, CA, May ...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
May 07, 2024 07:30 ET | Palisade Bio, Inc.
Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
May 02, 2024 08:30 ET | Palisade Bio, Inc.
Carlsbad, CA, May 02, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)
May 01, 2024 08:30 ET | Palisade Bio, Inc.
Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) before year end Carlsbad, CA, May 01, 2024 (GLOBE NEWSWIRE) -- Palisade...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach
April 23, 2024 08:30 ET | Palisade Bio, Inc.
– Collaboration grants Palisade Bio access to cutting-edge expertise and tools in bioinformatics – Partnership marks a significant value-driving milestone in Palisade Bio's mission to...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool
April 16, 2024 08:30 ET | Palisade Bio, Inc.
Company continues advancing ongoing development of targeted therapies for ulcerative colitis (UC) Carlsbad, CA, April 16, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI)...